Brain tumor initiating cell surface markers (BTIC markers)

Brain tumor initiating cells (BTICs), also known as brain cancer stem cells (BCSCs), are a specialized subpopulation of cells within brain tumors, most notably glioblastoma, that possess the hallmark properties of stem cells: self-renewal and the ability to differentiate into multiple lineages (Singh et al., 2004). These cells are identified and isolated using a variety of surface markers, including CD133 (Prominin-1), CD44, CD15 (SSEA-1), and Integrin alpha-6, which play functional roles in maintaining the stem cell niche and promoting tumor invasiveness (Lathia et al., 2015). BTICs are highly resistant to standard therapies, such as temozolomide and ionizing radiation, and are considered the primary drivers of tumor recurrence and progression (Bao et al., 2006). Therapeutic strategies targeting these markers, such as CAR-T cells (e.g., targeting IL13Ra2 or CD133) and monoclonal antibodies, aim to eliminate this resilient cell population (Brown et al., 2016). However, the clinical utility of these markers is complicated by their expression on healthy neural stem cells and the inherent phenotypic plasticity of glioma cells, which allows non-stem cells to transition into a stem-like state (Anido et al., 2010). Furthermore, the intra-tumoral heterogeneity of marker expression necessitates the development of multi-targeted or combinatorial approaches to achieve durable clinical responses.

Other names

Brain cancer stem cell markersGlioblastoma stem cell markersGSC markersBTIC surface antigensBrain tumor-initiating cell markers

Therapeutic agents target specific surface markers to induce direct cell lysis via immune-mediated mechanisms (e.g., CAR-T cells, ADCs) or inhibit signaling pathways (e.g., TGF-beta or Notch signaling) essential for maintaining the self-renewing stem cell population.